Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.

Abstract

Vindesine, a semisynthetic derivative of vinblastine sulfate, was tested for antitumor activity and clinical toxicity in 36 children. The drug was administered to the initial 13 patients entered into the study a 2 mg/m2/day for five days by IV bolus. Because of severe neurotoxicity and life-threatening gastrointestinal toxicity, the regimen in 23 patients was modified to 4mg/m2 IV infusion over four hours, weekly. This latter regimen was well tolerated, with acceptable gastrointestinal, hematological, and neurotoxicity. One child with acute lymphocytic leukemia resistant to vincristine had a transient M1 remission bone marrow. Improvement or stable disease was noted in one patient each with Ewing's sarcoma, neuroblastoma, and Hodgkin's disease.

• Authors: L J Ettinger, M Brecher, M Coleman, W A Smithson, R Patterson, E C Russell, T Necheles, B Jones, T Ohnuma
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 10 Issue 1 Pg. 35-43 ( 1982) ISSN: 0098-1532 [Print] United States
• PMID: 7038420 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Vinblastine
• Vindesine

Topics

• Adolescent
• Anemia (chemically induced)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Drug Administration Schedule
• Drug Evaluation
• Gastrointestinal Diseases (chemically induced)
• Humans
• Infant
• Leukemia, Lymphoid (drug therapy)
• Leukopenia (chemically induced)
• Vinblastine (adverse effects, analogs & derivatives, therapeutic use)
• Vindesine